- Home
- CAPR vs DRDB Comparison
CAPR vs DRDB Comparison
Compare CAPR & DRDB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAPR
- DRDB
- Stock Information
- Founded
- CAPR 2005
- DRDB 2024
- Country
- CAPR United States
- DRDB United States
- Employees
- CAPR N/A
- DRDB N/A
- Industry
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- DRDB
- Sector
- CAPR Health Care
- DRDB
- Exchange
- CAPR Nasdaq
- DRDB Nasdaq
- Market Cap
- CAPR 324.6M
- DRDB 315.3M
- IPO Year
- CAPR N/A
- DRDB 2024
- Fundamental
- Price
- CAPR $6.28
- DRDB $10.28
- Analyst Decision
- CAPR Strong Buy
- DRDB
- Analyst Count
- CAPR 8
- DRDB 0
- Target Price
- CAPR $24.75
- DRDB N/A
- AVG Volume (30 Days)
- CAPR 1.4M
- DRDB 91.6K
- Earning Date
- CAPR 08-11-2025
- DRDB 01-01-0001
- Dividend Yield
- CAPR N/A
- DRDB N/A
- EPS Growth
- CAPR N/A
- DRDB N/A
- EPS
- CAPR N/A
- DRDB N/A
- Revenue
- CAPR $13,392,150.00
- DRDB N/A
- Revenue This Year
- CAPR N/A
- DRDB N/A
- Revenue Next Year
- CAPR $6,061.53
- DRDB N/A
- P/E Ratio
- CAPR N/A
- DRDB $587.54
- Revenue Growth
- CAPR N/A
- DRDB N/A
- 52 Week Low
- CAPR $3.98
- DRDB $9.87
- 52 Week High
- CAPR $23.40
- DRDB $10.43
- Technical
- Relative Strength Index (RSI)
- CAPR 36.33
- DRDB N/A
- Support Level
- CAPR $6.17
- DRDB N/A
- Resistance Level
- CAPR $7.30
- DRDB N/A
- Average True Range (ATR)
- CAPR 0.43
- DRDB 0.00
- MACD
- CAPR -0.11
- DRDB 0.00
- Stochastic Oscillator
- CAPR 4.53
- DRDB 0.00
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
About DRDB Roman DBDR Acquisition Corp. II Ordinary shares
Roman DBDR Acquisition Corp II is a blank check company.